We are live on
!
Find out more
X
Xponance Portfolio holdings
AUM
$16.3B
1-Year Est. Return
44.61%
This Fund
S&P 500
This Quarter
Est. Return
-2.91%
1 Year Est. Return
+44.61%
3 Year Est. Return
+143.93%
5 Year Est. Return
+195.59%
10 Year Est. Return
+501.04%
AUM
$14.1B
AUM Growth
+$741M
(+5.6%)
Cap. Flow
+$1.58B
Cap. Flow
% of AUM
11.22%
Top 10 Holdings %
Top 10 Hldgs %
38.76%
Holding
1,735
New
165
Increased
1,464
Reduced
57
Closed
49
Avg Time Held
14.1
quarters
Top 10 Avg Time Held
19
quarters
Top 20 Avg Time Held
14.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$110M |
| 2 |
Apple
AAPL
|
+$89M |
| 3 |
Microsoft
MSFT
|
+$81.1M |
| 4 |
Amazon
AMZN
|
+$54.3M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$45.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Principal Financial Group
PFG
|
+$4.8M |
| 2 |
KeyCorp
KEY
|
+$4.08M |
| 3 |
Solstice Advanced Materials
SOLS
|
+$3.06M |
| 4 |
Valero Energy
VLO
|
+$2.61M |
| 5 |
Monster Beverage
MNST
|
+$2.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.95% |
| 2 | Financials | 11.04% |
| 3 | Consumer Discretionary | 10.62% |
| 4 | Communication Services | 10.59% |
| 5 | Healthcare | 9.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1351
IDEAYA Biosciences
IDYA
$3.31B
| $262K | ﹤0.01% |
7,866
+1,551
| +25% | +$52K |
2025 Q4
1 quarter
|
|
1352
Arcutis Biotherapeutics
ARQT
$3.28B
| $261K | ﹤0.01% |
11,085
+1,687
| +18% | +$43.1K |
2025 Q4
1 quarter
|
|
1353
McGrath RentCorp
MGRC
$2.8B
| $261K | ﹤0.01% |
2,363
+386
| +20% | +$42.9K |
2024 Q4
5 quarters
|
|
1354
Veracyte
VCYT
$3.47B
| $260K | ﹤0.01% |
8,086
+1,215
| +18% | +$45K |
2025 Q3
2 quarters
|
|
1355
Ultra Clean Holdings
UCTT
$2.76B
| $260K | ﹤0.01% |
+4,188
| New | +$215K |
2026 Q1
0 quarters
|
|
1356
Photronics
PLAB
$1.72B
| $259K | ﹤0.01% |
+6,407
| New | +$232K |
2026 Q1
0 quarters
|
|
1357
Nicolet Bankshares
NIC
$3.42B
| $259K | ﹤0.01% |
+1,742
| New | +$253K |
2026 Q1
0 quarters
|
|
1358
Tarsus Pharmaceuticals
TARS
$3.31B
| $258K | ﹤0.01% |
3,684
+610
| +20% | +$42.6K |
2025 Q4
1 quarter
|
|
1359
Provident Financial Services
PFS
$2.87B
| $258K | ﹤0.01% |
12,210
+2,021
| +20% | +$43.1K |
2025 Q2
3 quarters
|
|
1360
Rush Street Interactive
RSI
$2.2B
| $257K | ﹤0.01% |
+11,804
| New | +$226K |
2026 Q1
0 quarters
|
|
1361
Denali Therapeutics
DNLI
$2.94B
| $254K | ﹤0.01% |
13,240
+2,743
| +26% | +$54.6K |
2025 Q2
3 quarters
|
|
1362
Park Hotels & Resorts
PK
$3.14B
| $254K | ﹤0.01% |
24,121
+5,730
| +31% | +$63.3K |
2020 Q2
23 quarters
|
|
1363
Remitly
RELY
$5.03B
| $253K | ﹤0.01% |
16,132
+2,767
| +21% | +$40.9K |
2024 Q4
5 quarters
|
|
1364
USA Rare Earth Inc
USAR
$4.23B
| $251K | ﹤0.01% |
+16,613
| New | +$322K |
2026 Q1
0 quarters
|
|
1365
Unilever
UL
$135B
| $250K | ﹤0.01% |
4,396
+1,060
| +32% | +$71K |
2025 Q4
1 quarter
|
|
1366
Oscar Health
OSCR
$10.4B
| $250K | ﹤0.01% |
21,780
+5,908
| +37% | +$83.2K |
2024 Q2
7 quarters
|
|
1367
Waystar Holding Corp
WAY
$5.04B
| $250K | ﹤0.01% |
10,358
+1,657
| +19% | +$44K |
2025 Q1
4 quarters
|
|
1368
Dr. Reddy's Laboratories
RDY
$10.6B
| $250K | ﹤0.01% |
18,021
+4,868
| +37% | +$67.8K |
2025 Q1
4 quarters
|
|
1369
Delek US
DK
$4.94B
| $249K | ﹤0.01% |
+5,516
| New | +$197K |
2026 Q1
0 quarters
|
|
1370
Inspire Medical Systems
INSP
$1.99B
| $248K | ﹤0.01% |
4,817
+674
| +16% | +$47.2K |
2021 Q2
19 quarters
|
|
1371
SoundHound AI
SOUN
$2.17B
| $248K | ﹤0.01% |
36,126
+6,484
| +22% | +$56K |
2024 Q2
7 quarters
|
|
1372
Wipro
WIT
$17.8B
| $248K | ﹤0.01% |
117,063
+39,076
| +50% | +$95.2K |
2023 Q3
10 quarters
|
|
1373
Prudential
PUK
$29.3B
| $248K | ﹤0.01% |
8,727
+1,923
| +28% | +$59.2K |
2025 Q4
1 quarter
|
|
1374
H2O America
HTO
$2.45B
| $247K | ﹤0.01% |
+4,204
| New | +$229K |
2026 Q1
0 quarters
|
|
1375
InvenTrust Properties
IVT
$2.32B
| $246K | ﹤0.01% |
+8,090
| New | +$244K |
2026 Q1
0 quarters
|
|
Similar funds
PCM
LPC
MFG
PAM
BS
BBVA
NMO
PAS
Xponance's Q1 2026 Portfolio in Review
As of Q1 2026, Xponance held 1,735 positions worth $14.1B, up 5.6% from $13.3B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Xponance deployed $1.58B of net new capital in Q1 2026, opening 165 new positions and adding to 1,464 existing holdings. Its largest new stake was Medline Inc: 22,732 shares worth $1.01M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 38% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Principal Financial Group, an estimated $4.8M trimmed.
- Xponance's largest Q1 2026 buy was Medline Inc: 22,732 shares worth $1.01M.
- Xponance added most to NVIDIA in Q1 2026, an estimated $110M increase.
- Xponance's biggest Q1 2026 reduction was Principal Financial Group, cutting an estimated $4.8M.
- Xponance fully exited Confluent in Q1 2026, selling an estimated $1.34M.
- Xponance's ten largest holdings make up 39% of its $14.1B portfolio in Q1 2026.
- Xponance opened 165 new positions and closed 49 in Q1 2026.
- Xponance's portfolio value rose 5.6% quarter-over-quarter to $14.1B.
Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.